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Abstract
Among the acquired immunodeficiency syndrome (AIDS) drugs approved by the FDA for clinical use, two are modified cytosine analogs,
Zalcitabine (ddC) and Lamivudine [()3TC]. ()3TC is the only analog containing an unnatural L () nucleoside configuration. Similar to
other dideoxy nucleosides, these analogs are metabolically activated to the triphosphate that is incorporated into DNA by human
immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) resulting in DNA chain termination and ultimately cessation of viral
replication. The natural D (+) 3TC isomer also acts in a similar manner to inhibit HIV-1 RT. In cell culture, ()3TC is less toxic than its D (+)
isomer, (+)3TC, containing the natural nucleoside configuration, and both are considerably less toxic than 2V,3V-dideoxycytidine (ddC). The
mechanistic basis for the stereochemical selectivity and differential toxicity of the isomeric 2V,3V-dideoxy-3V-thiacytidine (3TC) and ddC
compounds is not completely understood although a number of factors may clearly come into play. We have previously investigated the
mechanistic basis for the differential stereoselective inhibition and toxicity of these three cytosine analogs by comparing the effects of 2V,3V-
deoxycytidine-5V-triphosphate (ddCTP), h-D-(+)-2V3V-dideoxy-3V-thiacytidine-5V-triphosphate [(+)3TC-TP] and h-L-()-2V3V-dideoxy-3V-
thiacytidine-5V-triphosphate [()3TC-TP] on the HIV-1 RT as well as a recombinant form of the human mitochondrial DNA polymerase
gamma (Pol g), the holoenzyme polymerase responsible for mitochondrial DNA replication. In this review, we discuss studies which may
provide insight into the molecular mechanism for the stereochemical selectivity and differential toxicity. D 2002 Published by Elsevier
Science B.V.
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1. Introduction
Virally encoded reverse transcriptase (RT) is required for
replication of the human immunodeficiency virus (HIV), an
etiological agent for acquired immunodeficiency syndrome
(AIDS). RT is considered to be the molecular target of
several therapeutic agents that interfere with HIV replica-
tion, including the 5V-O-triphosphates of 3V-azido-3V-deoxy-
thymidine (AZT), 2V,3V-didehydro-2V,3V-dideoxythymidine
(d4T), 2V,3V-dideoxycytidine (ddC) and the h-L-( )-2V,3V-
dideoxy-3V-thiacytidine [3TC, ()SddC]. Among all of the
nucleoside inhibitors currently used clinically, 2V,3V-dide-
oxy-3V-thiacytidine (3TC) is the only one with the unnatural
L-configuration. Most interestingly, 3TC has been shown to
be more potent and less toxic than the D-isomer [1–4]. The
mechanistic basis for the stereochemical selectivity and
differential toxicity of the isomeric 3TC and ddC com-
pounds is not completely understood although a number of
factors may clearly come into play. The differences in
potency and toxicity may be a combination of factors
including uptake, transport, metabolic activation, incorpo-
ration and degradation [1–3,5–9]. In addition, toxicity to
the host may also be related to inhibition of human
mitochondrial DNA polymerase gamma (Pol g) [8–10].
The mechanism of inhibition of HIV type 1 (HIV-1) RT
and Pol g by dideoxy nucleoside analogs such as 3TC and
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ddC [()SddC]1 involves in vivo phosphorylation to the
triphosphate [2V,3V-dideoxy-3V-thiacytidine-5V-triphosphate
(3TC-TP) and ddCTP] and subsequent incorporation into
the DNA primer strand resulting in chain termination. Thus,
in vitro studies have focused on evaluating the triphosphate
form of the analogs primarily using a steady-state kinetic
analysis to assess affinity and incorporation efficiency. These
steady-state methods are important to provide an initial
kinetic comparison; however, to obtain mechanistic and
quantitative information, a more detailed transient kinetic
analysis is required [11–13]. Our efforts to delineate the
molecular mechanisms of nucleoside analog inhibition of
HIV-1 RT and Pol g are based upon a transient kinetic ap-
proach using rapid chemical quench and stopped-flow fluo-
rescence methodologies. The important advantage of this
approach is the ability to observe directly events occurring at
the active site including binding events, protein conforma-
tional changes, and catalysis. The rate constants of individual
steps can be measured directly and any enzyme intermediates
including different conformational species that might be
formed can be observed directly. Using transient kinetic
methods, the rate of polymerization (kpol), the dissociation
constant for the ground state nucleotide binding (Kd) and
incorporation efficiency or specificity constant (kpol/Kd) for
the natural substrate, 2V-deoxycytidine-5V-triphosphate
(dCTP), as well as for 2V,3V-deoxycytidine-5V-triphosphate
(ddCTP), h-D-(+)-2V3V-dideoxy-3V-thiacytidine-5V-triphos-
phate [(+)3TC-TP] and h-L-()-2V3V-dideoxy-3V-thiacyti-
dine-5V-triphosphate [()3TC-TP] was assessed for HIV-1
RT and Pol g [14,15], using a synthetic 23/45-mer DNA/
DNA primer-template.
Our goal in this analysis is to develop an understanding
of the structure activity relationship (SAR) that allows a
correlation between the structural and stereochemical fea-
tures of nucleoside analog drugs with their kinetic and
mechanistic behavior toward relevant HIV-1 RT and host
polymerase targets such as Pol g. An in-depth understand-
ing of the mechanisms of inhibition of these enzymes may
be important in overcoming problems associated with tox-
icity. For example, if both the structural similarities and
differences were understood, this might identify features
important in selective interaction with HIV-1 RT over Pol g.
HIV-1 RT and Pol g both have the ability to carry out
DNA-dependent as well as RNA-dependent DNA synthesis.
In contrast to HIV-1 RT that has no proofreading activity,
and similar to many of the DNA polymerases, Pol g has 3V–
5Vexonuclease activity, which is believed to perform a
proofreading function [16,17]. It is possible that the failure
of 3V–5Vexonuclease of Pol g to efficiently remove chain
terminators may play a role in mitochondrial toxicity of
nucleoside analogs. However, discrepancies exist in the
literature concerning the efficiency of the exonuclease in
removal of these analogs and correlation to drug toxicity. It
has been proposed that efficient removal of 3V terminal
()3TC-MP by the 3V–5V exonuclease activity of Pol g
could be responsible for the low toxicity of ()3TC [9];
however, similar rates of exonuclease removal were re-
ported for the excision of 2V-deoxycytidine-5V-monophos-
phate (dCMP), 2V,3V-deoxycytidine-5V-monophosphate
(ddCMP) and ()3TC-MP from the 3V-terminus of a DNA
primer, even though there are significant differences in
mitochondrial toxicity [9]. We have also investigated the
exonuclease cleavage of Pol g by evaluating the excision of
dCMP, ddCMP, (+)3TC-MP, ()3TC-MP, and dTMP, from
the 3V-terminus of the corresponding DNA 23- or 24-mer
primer [15].
2. Results
2.1. A comparison of dNTP incorporation efficiency
A comparison of the kpol, Kd, and kpol/Kd values for each
dCTP analog for HIV-1 RT and Pol g is shown in Table 1. A
comparison of these analogs reveals that the natural sub-
strate, dCTP, serves as the best substrate for HIV-1 RT and
the human mitochondrial DNA g polymerase. In general,
the incorporation efficiency (kpol/Kd) for Pol g is much
higher than HIV-1 RT and thus a more proficient polymer-
Table 1
Comparison of incorporation efficiencies for modified dNTPs by HIV-1 RT or Pol g [15]
Polymerase dCTP
analogs
kpol (s
 1) Kd (AM) kpol/Kd
(AM 1 s 1)
Selectivitya
HIV-1 RT dCTP 1.88F 0.10 23.6F 5.0 0.080
ddCTP 0.35F 0.02 68.7F 11.4 0.0051 15.7
(+)3TC-TP 0.036F 0.003 43.5F 8.9 0.0008 100
()3TC-TP 0.019F 0.001 14.8F 2.8 0.0013 62
Pol g dCTP 44F 2 1.1F 0.1 40
ddCTP 0.66F 0.02 0.041F 0.007 16 2.5
(+)3TC-TP 0.35F 0.01 1.5F 0.1 0.23 179
()3TC-TP 0.125F 0.005 9.2F 0.9 0.014 2857
a Selectivity= (kpol/Kd)natural substrate/(kpol/Kd)analog taken from Refs. [14,15].
1 The abbreviation 3TC is most commonly used to refer to the un-
natural L or () isomer, ()SddC while the natural D or (+)SddC. While
we have used the common nomenclature in the literature, the most ap-
propriate chemical nomenclature for 3TC is ()-cis-1-[2-hydroxymethyl-
1,3-oxathiolan-5-yl]cytosine.
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ase. The selectivity values in Table 1 indicate the ability of
the polymerase to discriminate between the natural substrate
and the substrate analog. It is interesting to note that while,
in general, the Pol g has an overall higher level of discrim-
ination, the exception is ddCTP. In this case, Pol g has a
selectivity of 2.5 over dCTP while for HIV-1 RT, this value
is 15.7. It is surprising that Pol g incorporates ddCTP with
such a high level of efficiency. A second important dis-
tinction between the two polymerases relates to the issue of
stereochemistry and the selectivity for incorporating the
natural analog versus the unnatural one with the L-()
configuration. The HIV-1 RT incorporates the natural
(+)3TC-TP analog with a selectivity of only 1.6 over
()3TC-TP while Pol g is much more highly discriminating
on the basis of stereochemistry with a value of 16. The
affinity of ()3TC-TP for the enzyme–DNA complex is
six- to eight-fold weaker than that of the analog of (+)3TC-
TP, containing the natural nucleoside configuration. Accord-
ingly, Pol g incorporates the () isomer at least 16-fold less
efficiently than the (+) isomer as defined by the specificity
constants summarized in Table 2. This difference in incor-
poration efficiency is in good agreement with cell culture
studies with the nucleoside form of the compounds where
the (+)3TC isomer has been reported to be 25- and 12-fold
more toxic than the ()3TC in terms of inhibition of cell
growth and mitochondrial DNA synthesis, respectively [5].
2.2. Exonuclease activity
An in-depth analysis of Pol g 3V–5Vexonuclease re-
moval of ddC, (+) and ()3TC monophosphates (MP)
from duplex DNA with highly purified Pol g reconsti-
tuted holoenzyme complex was conducted [15]. Our
analysis was carried out using DNA substrates that were
3V-terminated with ddCMP (D24-ddC), (+)3TC-MP
[D24-(+)3TC] or ()3TC-MP [D24-(+)3TC], along with
the corresponding unmodified DNA 24-mers containing
dCMP (D24-dC). A summary of the rates of exonuclease
activity (kexo) for the holoenzyme complex of Pol g,
using various D24-mer substrates is shown in Table 3. In
spite of the slow excision rate, the exonuclease should
still effectively remove the 3TC-chain terminators with a
half-life of approximately 1 min. Although this will slow
the rate of mitochondrial DNA replication, the low rate
of 3TC incorporation will minimize the toxic effects.
In contrast, little or no DNA cleavage was observed for
D24-ddC, 12 h with the holoenzyme. The insusceptibility of
the 3V-terminal ddCMP to base excision was also reported
for a 3V–5Vexonuclease with porcine liver DNA polymerase
g [18]. Similar results have been reported in studies on yeast
mitochondrial DNA polymerases, where the terminally
incorporated ddTMP, AZTMP, and ddCMP were not
removed by the 3V–5Vexonuclease activity of Pol g [19].
This striking observation may explain why inhibition of
mitochondrial DNA synthesis by ddC is so profound.
3. Discussion
Our studies have shown that ()3TC-TP is less effi-
ciently incorporated than (+)3TC-TP into DNA by Pol g
and both are incorporated less efficiently than ddCTP.
Moreover, the efficiency of incorporation by Pol g is
directly correlated with toxicity of each nucleoside analog.
These observations point to incorporation by Pol g into
mitochondrial DNA as a major site of toxicity of nucleoside
analogs. The availability of reliable preparations of Pol g
[20] now affords a rapid method to screen drugs for toxicity
and opens the path toward further structure/function studies
to aid in the design of less toxic analogs.
The unnatural L-() configuration of ()3TC seems to
play an important role in preserving the anti-viral activity
while decreasing the inhibitory effect on the host Pol g. This
example suggests that other unnatural nucleoside analogs
may show similar effectiveness combined with low toxicity.
In contrast, the effects of inhibition on mitochondrial
DNA synthesis in vivo and in vitro by ddC are profound
[21,22]. The IC50 value for ddC relative to the (+) and ()
isomers of 3TC, indicated that ddC is 180- and 2300-fold
more toxic than the (+) and () isomers, respectively [3]. A
number of factors may clearly come into play including
uptake, transport, metabolic activation, degradation and
removal from the system, but our studies have shown a
lack of exonucleolytic removal of a 3VddC that may sig-
nificantly contribute to drug toxicity. Conversely, analogs
that activate the exonuclease removal by Pol g may exhibit
Table 2
Understanding the molecular basis for differential toxicity of modified
cytosine analogs [15]
dNTP Relative
incorporationa
Relative
exonucleaseb
Relative
toxicityc
ddCTP 1140 < 0.001 2300
(+)3TC-TP 16 1.2 12
( )3TC-TP 1 1 1
a Calculated from kpol/Kd for each nucleotide from Table 1.
b Calculated from the observed exonuclease rate from Table 3.
c From Ref. [5] in which the nucleoside form of the analogs are
assessed.
Table 3
Comparing the removal of DNA chain terminated substrates by Pol g
exonuclease activity [15]
DNA substrates primera Holoenzyme kexo (s
 1)
D24-dC 0.022F 0.001
D24-ddC < 0.00001b
D24-(+)3TC 0.012F 0.001
D24-()3TC 0.010F 0.001
a All of the templates used in this study were a DNA 45-mer.
b The minimum estimate of the rate of hydrolysis was calculated from
the observation that less than 1% of the DNAwas hydrolyzed after 12 h of
incubation with the holoenzyme [15].
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even lower toxicity; and this may provide a new avenue for
exploration of less toxic drugs. Clearly, additional studies
are required to identify the structural features of nucleoside
analogs that may be utilized to obtain selectivity for HIV-1
RT over DNA Pol g.
4. Conclusions and perspectives
In summary, our studies have demonstrated that the
(+)3TC-TP is a more potent inhibitor for human mitochon-
drial DNA Pol g than the () isomer, through tighter
binding and faster incorporation rate into a DNA duplex,
leading to greater toxicity [15,23]. Using highly purified Pol
g, there is no significant difference in the excision of the
incorporated (+) and ()3TC-MP by the 3V–5Vexonuclease
activity of Pol g from the 3V-terminus of a DNA primer,
indicating this step likely does not contribute to the low
toxicity of ()3TC. Additionally, our studies have shown
that a terminally incorporated ddCMP is not efficiently
removed by the 3V–5Vexonuclease activity of Pol g, suggest-
ing this may play a role in the high level of inhibition of ddC
on mitochondrial DNA synthesis observed in vitro and in
vivo. The overall toxicity of a nucleoside analog towards
replication will be a function of the frequency of incorpo-
ration of the chain terminator and the kinetics of excision by
the proofreading exonuclease, relative to the rate of DNA
replication required to sustain growth. We can now quantify
these parameters and begin to assess the structural/func-
tional determinants that govern nucleotide selectivity for Pol
g in each step.
An in-depth understanding of the mechanism of inhibition
of DNA polymerase g is important in defining the cytotox-
icity of anti-HIV drugs towards mitochondrial replication. A
knowledge of the mechanistic and structural similarities and
differences between Pol g and HIV-1 RT may identify key
features important for selective drug incorporation by the
viral HIV-1 RT but not by Pol g and therefore facilitate the
design of less toxic, viral-specific AIDS drugs.
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